For the past 10 months, Sen. Claire McCaskill (D-Mo.) has asked Teva Pharmaceuticals (TEVA) to provide information about any steps the drug maker has taken to mitigate the opioid epidemic. But the company has refused to comply, prompting the lawmaker to write the Department of Defense and Department of Veterans to reconsider their dealings with Teva.

In identical letters to the agencies (here and here), McCaskill wrote that Teva has been “stonewalling” her probe into the opioid crisis, which she launched last year into several drug makers and wholesalers. And she urged the agencies to “evaluate whether (the DOD and VA) should contract with an entity that has refused to respond to requests during a Senate investigation.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Given that the combined drug purchases average less that $1 million USD per year, one wonders if the Senator picked a target that was indeed “replaceable / expendable” in the grand scheme of things. Then again, it may indeed be on principle. “Call me in six months.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy